Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse.

Saved in:
Bibliographic Details
Title: Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse.
Authors: Huang CH; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.; Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan., Chen JY; Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.; Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung, Taiwan., Chang HY; Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung, Taiwan.; Institute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, HsinChu, Taiwan., Hong WZ; Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.; Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung, Taiwan., Jiang YW; Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.; Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung, Taiwan., Lee CY; Innovation Frontier Institute of Research for Science and Technology, National Taipei University of Technology, Taipei, Taiwan.; Department of Electrical Engineering, National Taipei University of Technology, Taipei, Taiwan., Wu CH; Bioinformatics and Biostatistics Core, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan., Lin YS; Department of Chest Surgery, China Medical University Hospital, Taichung, Taiwan., Tsai YY; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.; Department of Colorectal Surgery, China Medical University Hospital, China Medical University, Taichung, Taiwan., Kao WL; Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan., Chao KSC; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.; Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan.; Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung, Taiwan., Huang KC; Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan. chihyang0425@mail.cmu.edu.tw.; Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung, Taiwan. chihyang0425@mail.cmu.edu.tw.; Translation Research Core, China Medical University Hospital, China Medical University, Taichung, Taiwan. chihyang0425@mail.cmu.edu.tw.; Office of Research and Development, Asia University, Taichung, Taiwan. chihyang0425@mail.cmu.edu.tw.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Feb 25; Vol. 75 (3). Date of Electronic Publication: 2026 Feb 25.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1432-0851
DOI:10.1007/s00262-026-04336-9